Pea clinical trials
How each study uses pea is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pea studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 4
S&R Farmaceutici S.p.A. (1) · Liaquat University of Medical & Health Sciences (1) · University of Exeter (1) · University of Cagliari (1) · University of Udine (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses pea is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Endocannabinoid Activity Remodulation for Psychosis Liability in YouthRecruitingNot applicableUniversity of UdineNCT06037993Written as Ultra-micronized Palmitoylethanolamide (PEA)
- Ultra-Micronized vs Liposomal PEA 600 mg: A Crossover PK Study in Healthy SubjectsCompletedNot applicableS&R Farmaceutici S.p.A.NCT07804758Written as liposomal PEA
- Study to Investigate the Potential Pharmacological Effect of Oral Palmitoylethanolamide (PEA) Therapy in the Management of Low Back Pain (Neuropathic Pain)CompletedNot applicableLiaquat University of Medical & Health SciencesNCT06694337Written as 300 mg Palmitoylethanolamide (PEA) Phytosome®
- Vegan or Animal Protein Ingestion on the Recovery of Muscle Function Following ExerciseCompletedNot applicableUniversity of ExeterNCT04156386Written as Recover vegan (26g pea) protein supplement
- Efficacy of Palmitoylethanolamide-polydatin Combination on Chronic Pelvic Pain in Patients With EndometriosisCompletedNot applicableUniversity of CagliariNCT02372903Written as Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin
Codes
What other systems call pea · ClinicalTrials.gg INT018308
- UNII (FDA) W4X7H8GYFMPEAOne source FDA
- RxNorm 1426912One source FDA
- NCI Thesaurus C72056PeaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W4X7H8GYFM | PEA | One source FDA |
| RxNorm | 1426912 | — | One source FDA |
| NCI Thesaurus | C72056 | Pea | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.